ReviewJournal of neuro-oncology2026
Loss of pituitary hormone function after stereotactic radiosurgery for pituitary adenomas: mechanisms and management.
Review in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pituitary Society Delphi consensus on the role of radiotherapy for pituitary adenomas.Pituitary · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStereotactic radiosurgery (SRS) is an essential modality for treating recurrent or residual pituitary adenomas (PAs), offering high rates of tumor control and moderately effective endocrine management in both functioning (FPAs) and non-functioning pituitary adenomas (NFPAs). Endocrine remission is less consistently achieved, and in hypersecretory states such as acromegaly and Cushing's disease, hormone normalization may be delayed by years relative to surgical resection. The impact of pre-treatment hormone suppression on radiosensitivity remains controversial, with evidence suggesting it may further delay endocrine remission.
methodsA review of the literature was conducted to evaluate the rates and predictors of hypopituitarism following SRS for pituitary adenomas, the differential radiosensitivity of pituitary axes, and strategies aimed at reducing radiation induced endocrinopathy.
resultsHypopituitarism remains the most common complication of SRS, occurring in 21-50% of patients, and arises from radiation-induced damage to the hypothalamus, pituitary gland, or stalk. The radiosensitivity of pituitary axes varies across studies; while some series identify the somatotropic axis as most vulnerable followed by the gonadotropic, corticotropic, and thyrotropic axes, larger multicentric cohorts have reported thyrotropin and cortisol deficiencies as more prevalent. Hypopituitarism may develop years after treatment, underscoring the importance of long-term followup. Advances in volumetric and automated segmentation imaging have improved tumor targeting and reduced unintended radiation exposure to adjacent structures, while strategies such as pituitary transposition and optimized dose protocols have shown promise in mitigating radiation-induced endocrinopathies.
conclusionCurrent evidence underscores the importance of individualized treatment planning, careful dose modulation, and advanced imaging techniques to minimize complications while maintaining therapeutic efficacy. Further research is needed to clarify predictors of hypopituitarism, optimize treatment protocols, and explore strategies to enhance patient outcomes following SRS for pituitary adenomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.